Abstract
BackgroundHIV-infected children are at a higher risk of Invasive Pneumococcal Disease (IPD) and its mortality, even in the era of antiretroviral therapy. Therefore, an effective vaccination strategy would be beneficial. To investigate the effectiveness of Pneumococcal Conjugate Vaccination (PCV) against IPD among HIV-Infected and HIV-Uninfected Children through a systematic review and meta-analysis.MethodsObservational studies and randomized trials on 7 years old or older children were searched in the Cochrane Library, Web of Science core collection, Embase, Medline/PubMed, and Google Scholar. Critical appraisal was done using the Cochrane risk of bias tool and the Newcastle-Ottawa quality assessment form. Effectiveness and efficacy of at least one dose of PCV was investigated among children with and without HIV considering subgroups of pneumococcal serotypes. We meta-analyzed the effect sizes using random-effects modeling.ResultsEfficacy of PCV was estimated as 45.0% (31.2, 56.1) and 52.6% (25.7, 69.8) among HIV-infected and HIV-uninfected children, respectively. Effectiveness of PCV among HIV-infected children as − 6.2% (− 67.6, 32.7) was significantly lower than HIV-uninfected children 65.1% (47.3, 76.9). Effectiveness of PCV among HIV-infected children for IPDs caused by vaccine serotypes was estimated as 7.7(− 66.7, 48.9), and for IPDs caused by non-vaccine serotypes was estimated as − 402.8(− 1856, − 29.2).ConclusionUnlike the evidence on the efficacy of PCV against IPD among both of HIV-infected and HIV-uninfected children, its effectiveness against IPD among HIV-infected children is much less limited.Review registrationThe study protocol was registered at PROSPERO (registration ID: CRD42018108187).
Highlights
HIV-infected children are at a higher risk of Invasive Pneumococcal Disease (IPD) and its mortality, even in the era of antiretroviral therapy
Based on case-control studies, the overall effectiveness of Pneumococcal Conjugate Vaccination (PCV) against any IPD was estimated as − 6.2% and 65.1% among HI and Children Without HIV Infection (HUI) children, respectively
The results showed that the overall effectiveness of PCVs in preventing IPD among HI children was significantly lower than HUI children (− 6.2% vs. 65.1%)
Summary
HIV-infected children are at a higher risk of Invasive Pneumococcal Disease (IPD) and its mortality, even in the era of antiretroviral therapy. Children with HIV-infection (HI) are prone to invasive pneumococcal disease (IPD) roughly 40 times more than those without HIV-infection (HUI) [1, 2]. The risk of IPD-related mortality among them is higher than children without HIV-infection (HUI) [3, 4]. Of the most appropriate preventive strategies, for the time being, may be boosting the immune system function through antiretroviral therapy (ART) and/or vaccination against pneumococcal diseases [2]. Effective vaccination can prove to be an important strategy for prevention of IPD and IPD-related mortality in HI [8, 9].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.